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Heparan sulphate (HS) and chondroitin sulphate
(CS) proteoglycans (PGs) frequently have opposite
biologicfunctions in cell-matrix adhesion as well as
in the regulation of cell proliferation. Data revealed
that sulphated glycosaminoglycans (sGAGs) (sugar
chains of PGs) are differently expressed in tumor
cells characterized by different metastatic potential;
the more metastatic cells contain a higher HS/CS ra-
tio. As theproliferative capacity oftumor cells is also
frequently altered in parallel with their metastatic
potentia4 it was not clear whether observed PG al-
terations reflect changes in cellproliferation or met-
astatic potential The cell-associated PG expression
and sGAG biosynthesis was studied in tumor cells of
human melanoma lines characterized by different
experimental metastaticpotential to the mouse liver
but similar in vitro/in vivo proliferation rates. Using
antibodies againstPGs wefound different expression
ofPG epitopes in melanoma lines, except from the
melanoma antigen. Unlike the low CSPG (melCSPG)
metastatic melanoma cells; the cell line with high
metastatic capacity contained a higherproportion of
positive cellsfor surface-HSPG without the coexpres-
sion of certain cartilage-type CSPG epitopes (recog-
nized byMAb HSFPG 529) as well as by an increased
pericellularHS/CS ratio due to intracellular accumu-
lation/retention of CS. Immunocytochemistry of ad-
herent cells revealed HSPGs at substrate-attached
membrane areas only in cases of highly metastatic
melanoma cells These datafurther support our view
that the absolute or relative dominance of HSPGs
over CSPGs at the cell surface of metastatic tumor
cells can be considered a marker of a more meta-
static phenotype. (AmJPathol 1992, 141:467-474)
Cell membrane proteoglycans (PGs) are known to be
involved in cell-cell and cell-matrix interactions.1 Some of
them are extracellular components like the large PGs ag-
grecan, perlecan, and versican, or the small PGs decorin
and fibromodulin1' belonging to the chondroitin sul-
phate proteoglycan (CSPG), aggrecan, versican, and
decorin, or the heparan sulphate proteoglycan (HSPG),
perlecan, family. Interest has been focused on cell mem-
brane-type PGs. Important members of this subgroup
are syndecan and betaglycan; both are glycosylated by
heparan sulphate (HS) and chondroitin sulphate (CS)
chains,34 fibroblast-membrane HSPGs5 and CSPG as-
sociated with MHC-11.1 3
PGs were implicated in the regulation of cell
growth.68 It was demonstrated that the membrane
HSPG, betaglycan, serves as coreceptor for transform-
ing-growth factor-p (TGF,), providing and/or concentrat-
ing TGFP for the signaling-TGFO receptor.9 Another
membrane HSPG was shown to serve as a captive de-
vice for FGF through its HS side chains, a link essential for
FGF effect.1"12 The sugar chains of HSPGs, HS and
heparin, were also shown to have a direct role in the
regulation of the proliferation of smooth muscle, endothe-
lial, and tumor cells.6,13
Transformed cells are frequently characterized by al-
tered GAG pattern, decreased HS, and increased CS
content,1315 as well as accumulation of HSPG and HS in
the Golgi region.16 Well-characterized human tumor PGs
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are the meICSPG,17'18 HSPG of colon carcinoma,19 and
glioma.' Meanwhile, the function(s) of tumor cell PGs is
not clear. The most important consequence of the malig-
nant transformation is the ability of tumor cells to invade
host tissues and form distant colonies, i.e., metastases.
Data show that rodent tumors with different metastatic
capacity are characterized by altered sGAG pattern;
there is frequently an increased HS/CS ratio in more met-
astatic variants.21
We have established and described human mela-
noma xenograft lines, HT168/HT168-Mi, with different
liver-colonizing potentials.21'22 In this model there is no
difference in cell proliferation characteristics or expres-
sion of melanoma markers.22 However, using this model
this study describes increased HSPG and decreased
CSPG epitope expression on the surface of highly met-
astatic cells. The alterations at the PG level were also
reflected in the glycosylation pattern; due to a decreased
CS content, the HS/CS ratio increased in the pericellular
compartment of highly metastatic cells. In situ immuno-
chemistry showed surface and substrate attachment site
accumulation of HSPG epitopes only in the case of highly
metastatic human melanoma cells.
Materials and Methods
Human Melanoma Xenografts
HT168 human melanoma xenograft was established
from human melanoma cell line A205821 (provided by
L.A. Liotta, NCI, Bethesda, MD). HT168-Mi xenograft
was derived from liver metastasis of HT168 tumor.22
HT168-M1 cells proved to be eight- to tenfold more met-
astatic than the HT168 cells in liver-colonization assay
after intrasplenic injection of 106 cells.22
In Vitro Cultures
HT168 cell line was established from the sc tumor
whereas HT168-M1 was from a liver metastasis of the
HT168 tumor; both were cultured in RPMI 1640 medium
(Gibco, Grand Island, NY) supplemented with 10% fetal
calf serum (FCS) (Boehringer, Mannheim, Germany) at
370C in 5% C02. The cells were either scraped from the
plastic surfaces by rubber policeman or digested at room
temperature by 0.2% trypsin for 5 minutes. The human
and melanoma character of the tumor cells was tested
regularly by chromosomal analysis as well as by measur-
ing the expression of human and melanoma antigens.22
Biosynthetic Labeling of GAGs
Cells in stationary growth phase (1 C5 cells/cm2) were in-
cubated with a medium containing 10 ,uCi/ml 3H-
glucosamine (8 mC/mmol, CEA, Saclay, France) for 24
hours at 37°C. The medium was removed, and the cells
were washed with 3 x 5 ml phosphate-buffered saline
(PBS) and digested by 0.05% trypsin/PBS for 15 minutes
at room temperature. The trypsinization was stopped by
adding 20 ,ul FCS. Cells were scraped from the plastic,
sedimented at 2000 rpm for 5 minutes at 40C, and the
supernatant, containing the pericellular proteins, was re-
moved. The cell pellet was washed with 2 x 1 ml PBS.
Separation of GAGs
The sugar chains were released from the PG core pro-
teins by reductive alkaline hydrolysis in 0.05 mol/l NaOH
in the presence of 1 mol/l NaBH4 at 450C for 24 hours.
The hydrolysates were desalted on Biogel P2 column
equilibrated with 10 mmol/l Tris-HCI, pH 8.2. The ex-
cluded 3H-macromolecules either were precipitated by
cetylpyridinium chloride (CPC) or were submitted to ion-
exchange chromatography using DEAE-Trisacryl col-
umn (IBF, France), equilibrated with 10 mmol/A Tris-HCI
buffer, pH 8.2. Elution was performed with linear NaCI
concentration gradient.
Characterization of GAGs
Analytical scale precipitation of 3H-GAGs was carried out
according to Wasteson.23 CS was identified by its sensi-
tivity to chondroitinase AC (Seikagaku-Kogyo, Japan),
whereas HS was identified by deaminative cleavage with
nitrous acid. The specific degradation was assessed
from the elution diagrams of the starting materials and the
hydrolysates obtained on a Biogel P6 column using 0.2
mol/l acetic acid-pyridine, pH 5.0.
Anti-PG Antibodies
Anti-CSPG Antibodies
ME.31.3, an IgGl (provided by Dr. M. Herlyn, Wistar
Institute, Philadelphia, PA), was produced against core
protein epitope of a 250 kd melanoma associated CSPG
antigen.24
HFPG-529/4 (IgM) and MK1 72 (IgGl ) were produced
against human fetal articular cartilage CSPG recognizing
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core protein epitopes at the linkage region of the CS
stub.25'26
Anti-HSPG Antibodies
FW16 antibody produced against pig skin fibroblast
membrane HSPG (mw 60 kd) recognizing a core protein
epitope was provided by M. F. Watt (ICRF, London, UK).
BN42 antibody produced against rat liver basement
membrane HSPG (J.V. Hascall, NIH, Bethesda, USA)
was a gift of B. Nusgens (Liege University, Liege, Bel-
gium).27
Flow Cytometry and Indirect
Immunofluorescence
For flow cytometry, confluent phase melanoma cells were
collected by scraping or by trypsinization, suspended
(106 cells/sample), and labeled at 40C (native cells) or
after 10 minutes of fixation in methanol (MetOH). For im-
munofluorescence, cells were grown on glass coverslips
at a density of 1 05 cells/cm2.
Cells in suspension or on coverslips were labeled ei-
ther at 40C or room temperature. First, 10% nonimmune
goat serum was applied for 10 minutes, then the samples
were incubated with the primary antibody (1 :100 working
dilution for monoclonals and 1:50 for polyclonals) for 30
minutes. After washings in PBS (three times), an appro-
priate FITC-labeled secondary antibody (goat anti-
mouse IgG or goat anti-rabbit IgG, Nordic) was applied
(working dilution 1:20 in PBS) for another 30 minutes.
After another washing in PBS (three times), the unfixed
samples were fixed in 1% paraformaldehyde/PBS (10
min), while the fixed ones were kept in PBS at 40C. Neg-
ative controls for flow cytometry or immunofluorescence
were exposed to the secondary FITC-labeled antibody
alone. Experiments in which the background fluores-
cence was higher than the autofluorescence of unstained
cells were excluded from this study. Cells adherent to
coverslips were viewed and photographed in a Vanox-
Olympus epiluminescence microscope or in a confocal
laser scanning microscope (BRL). Cell suspensions were
tested in FACStar flow cytometer (Becton Dickinson,
Sunnyvale, CA) by measuring at least 104 cells/sample
(in triplicate) and the percent of positive cells (the fluores-
cence of which was higher than the intensity of 90% of
the negative control population) was determined.
Results
Flow Cytometric Analysis and Localization
of CSPG Epitopes
The surface of HT1 68 and HT1 68-Mi cells were equally
positive for the melanoma-CSPG antigen (-60%). One of
the cartilage CSPG epitopes, detected by MAb MK1 72,
was equally represented, though at a low level, on the
surface of the melanoma cells, but another cartilage,
CSPG epitope, recognized by MAb HFPG529, was
present only on the native low metastatic HT1 68 cells
(Table 1). After MetOH fixation, which allows the detec-
tion of intracellular antigens as well, similar CSPG antigen
pattern was detected in the two cell populations (Table
1). The lower proportion of positive cells in fixed samples
compared with the native ones is probably due to the loss
of antigenicity upon fixation. In the adherent cells of both
lines, the melanoma CSPG antigen was present at the
apical cell surface and in the cytoplasm (Figure 1). In
permeabilized adherent cells, MAb HFPG529 bound dif-
fusely to cytoplasmic domains of the low metastatic
HT1 68 cells (Figure 2a) but it did not label the high met-
astatic variant (Figure 2b). There was a diffuse faint cy-
toplasmic positivity in a small subpopulation of cells in
both tumor cell lines reacted with MAb MK1 72 antibody
(not shown).
Flow Cytometry and Localization of
HSPG Epitopes
On the surface of native highly metastatic HT168-Mi
cells, the two anti-HSPG antibodies were detected at low
frequency (15%) but HT1 68 cells remained negative (Ta-
ble 2). The majority of the HSPG epitopes on HT1 68-M1
cells were masked according to the significantly in-
creased surface labeling after trypsinization (Ta-
Table 1. Expression of CSPG Antigens in Human Melanoma Cells (Flow Cytomety)
Cell surface Cell surface + cytoplasm
Antibodies HT168 HT1 68-Mi HT168 HT1 68-Mi
ME.31.3 51.5 + 10.3 69.4 ± 15.4 41.8 ± 11.7 37.2 ± 7.6
HFPG529 47.8 ± 9.2 0.5 ± 0.4 40.6 ± 8.3 0.0 ± 0.0
MK172 20.6 ± 5.2 28.5 ± 6.3 23.6 ± 4.2 22.2 ± 3.3
Data are expressed in % of positive cells. Each point represents mean of three measurements (±SD). Cell surface; immunolabeling of native
cells at 40C. Cell surface + cytoplasm = immunolabeling of MetOH fixed cells.
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Figure 1. Immunofluorescent localization of melanoma-CSPG
antigen in adherent HT168 cells. Methanol fixation/perme-
abilization; primary Ab: ME.31. 1, secondary antibody: goat anti-
mouse IgG-FITC Note the heterogenous staining of the apical cell
surfaces (arrows), x 600.
Figure 2. Immunofluorescent localization ofcartilage-type CSPG
antigen in adherent human melanoma cells. Methodology as in
Figure 1, but the primary antibody was MAb HFPG529. a: In the
HT168 line there is a diffuse cytoplasmic staining in some cells
(arrows) but negative cells are morefrequent, x 600; b: HT168-Mi
cells are uniformly negative, x 600.
ble 2). One of these antigens, recognized by the poly-
clonal antibody PAb BN42, was also masked on the sur-
face of a small proportion of HT1 68 cells (Table 2). After
MetOH fixation, both cell lines exhibited cytoplasmic pos-
itivity. The PAb FW1 6-positive cells are dominant over
PAb BN42-positive ones in the low metastatic HT168 cell
population. In the highly metastatic HT168-Mi cells, the
expression of epitopes recognized by PAb FW1 6 was
lower than in HT168 cells, while the HSPG epitope, rec-
ognized by PAb BN42, was similarly represented (Ta-
ble 2).
In adherent cells, PAb FW1 6 was completely absent
from the apical surface of HT1 68 cells (Figure 3a) but
was diffusely present on HT1 68-M1 cells as discrete do-
mains (Figure 3b). This difference disappeared after per-
meabilization because both cell types showed positivity
with PAb FW16. In the cytoplasm of the adherent low
metastatic HT1 68 cells, the distribution of PAb FW1 6-
recognized antigen was diffuse (Figure 4a). While in
HT168-M1 cells, beside the diffuse cytoplasmic localiza-
tion, these epitopes were concentrated at the focal con-
tact areas at lamellopodia and filopodia (Figure 4b). The
difference between the two cell types in the labeling of
the ventral membranes with PAb FW1 6 was further sup-
ported by confocal laser scanning microscopic analysis
(Figure 5a, b). The staining pattern of PAb BN42 at the
cell surface and in the cytoplasm was essentially the
same than in the case of PAb FW1 6 (not shown).
Biochemistry of Cell-associated sGAGs
The incorporation of 3H-glcN into cell-associated sGAGs
was predominant in the pericellular (surface) compart-
ment compared with the intracellular one, which repre-
sented only one-fifth and one-fourth of the total cellular
incorporation in HT1 68 and HT1 68-M1 cells, respectively
(Table 3). There was no difference in the precursor incor-
poration into the pericellular sGAGs, but a 50% increase
was detected in the incorporation into intracellular sGAGs
in HT168-Mi cells compared with HT168 (Table 1).
After ,8-elimination and ion-exchange chromatogra-
phy, different sGAG composition was found on the sur-
face of the two melanoma lines. There was no difference
in the precursor incorporation into HS but due to the lower
level of incorporation into CS in HT168-Mi cells, the HS/
CS ratio was three-fold higher on the surface of the high
metastatic cells (6:1) than on the low metastatic counter-
part (2:1) (Figure 6). Intracellularly, there was no differ-
ence between the two cell lines in the precursor incorpo-
ration into HS but due to the increased incorporation into
Table 2. Expressions ofHSPG Antigens in Human Melanoma Cells (Flow Cytomety)
Cell surface Cell surface-masked Cell surface + cytoplasm
HT168 HT168-M1 HT168 HT168-M1 HT168 HT1 68-M1
FW16 0.0 ± 0 13.6 ± 2.9 1.5 ± 0.8 30.3 ± 8.2 73.7 ± 9.2 47.5 ± 6.0
BN42 0.0 ± 0 18.7 ± 5.6 21.5 ± 7.2 71.5 ± 7.0 27.9 ± 5.4 37.2 ± 4.4
Data is expressed in % of positive cells. Each point represents mean of three measurements (-SD). Cell surface = immunolabeling native
cells at 40C. Cell surface-masked = immunolabeling of trypsinized cells at 40C. Cell surface + cytoplasm = immunolabeling after MetOH
fixation.
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Figure 3. Immunofluorescent localization
of membrane-type HSPG epitopes on the sur-
face of adherent human melanoma cells.
Methodology: 40C labeling with PAb FWJ6
and goat anti-rabbit IgG-FITCG a: There zs no
labeling on the surface ofHT168 cells. X900.
b: Membrane-HSPG epitopes are localized
into discrete surface domains (arrows) in
HT168-Mi cells. X900.
Figure 4. Immunofluorescent localization
of memnbrane-type HSPG epitopes in humtan
melanoma cells. Methodology: methanol fix-
ation/permeabilization, immunlabeling as in
case ofFigure 3. a: There is a diffuse cytoplas-
mic-mostlypermnuclear-staining in HT168
cells (arrow), x 1600. b. In HT168-Ml cells
HSPG epitopes (recognized by PAb FWJ6) are
concentrated at those plasma membrane ar-
eas, which are in contact with the solid sub-
strate (arrow), x 1600.
CS in the highly metastatic cells, the ratio between HS
and CS was much lower (around one) in HT1 68-M1 cells
than in the HT168 (around two) (Figure 6). Based on
these data, we concluded that the different sGAG com-
position in the two cell lines is not due to different HS
biosynthesis, but rather due to the intracellular accumu-
lation or retention of CS in the highly metastatic cells.
Discussion
The biosynthesis of PGs and their GAG chains is altered
during malignant transformation, resulting in a decreased
HS sulphation and/or production and increased CS con-
tent in the majority of tumor types.13 The GAG expression
is altered in tumor cells during progression and metasta-
tization.21 In several rodent and in some human metasta-
sis models the increased metastatic capacity is associ-
ated with an increased HS/CS ratio in sGAGs.21 We have
studied these phenotypic changes in human melanoma
xenografts, HT1 8/HT1 68, characterized by different pro-
liferation rate as well as experimental liver metastatic ca-
pacity.21 In this model, we found an increased HS/CS
ratio in sGAGs in the more metastatic tumor but the total
GAG content was not altered.21 Due to the fact that be-
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Figure 5. Confocal laserscanning microscopy ofadherentbhuman
melanoma cells labeled for intracellular membrane-type HSPG
epitopes. Methodology: as in the case ofFigure 4. Six serial optical
sections (1 Fm) werephotographed in case ofan area. Upper left:
apical membrane; lower right: substrate attached site. a: HT168
cells. Note the diffuse cytoplasmic staining (upper center and right)
and the lack of labeling at attachment membranes (lower right),
X500. b: HT168-Ml cells. Note the continuous membrane label-
ing as well as a significantfluorescence at the membranes attached
to substrate (lower right), x500.
side the metastatic capacity, the proliferation rate was
also different in these melanomas, it was not clear how
the difference in sGAG-composition was related to the
biological properties. To approach the problem, we have
established human melanoma xenograft lines (HT168/
HT168-Mi) with different liver metastatic capacity but
similar in vivo/in vitro growth rate.22 In this model, we
found again characteristic differences in cellular PG ex-
pression. In the cell-associated sGAG compartment,
there was only a slight difference between the two tumor
lines, unlike in the relative ratio between HS and CS of the
Table 3. Incorporation of3H-glcN into Cell-associated
sGAGs in Melanoma Cells
sGAG fraction HT168 HT168-M1
Pericellular 76.83 ± 8.2 81.13 ± 4.5
Intracellular 18.90 ± 1.8 28.00 ± 1.4
Data are expressed as cpm X103/105 cells and represent
means of three measurements ± SD. Cells were labeled with 3H-
glcN, the peri- as well as the intracellular fractions were separated
and sGAGs were isolated using p-elimination and ion-exchange
chromatography.
individual fractions (surface or intracellular). The intracel-
lular sGAG was the minority of total cellular sGAGs and
the highly metastatic variant, HT1 68-M1, contained 50%
more intracellular sGAG due to the increased CS content
than the low metastatic HT1 68. However, the intracellular
HS content was similar in the two cell types. More pro-
nounced differences were found in the pericellular (sur-
face) sGAG composition; the HS/CS ratio increased on
highly metastatic melanoma cells due to a decrease in
CS content.
In harmony with these observations, flow cytometric
measurements revealed characteristic differences be-
tween the two melanoma lines in the expression of PG
epitopes. A cartilage-CSPG recognizing antibody, MAb
HFPG529, did not bind to the highly metastatic mela-
noma cells unlike its low metastatic counterpart. MAb
HFPG529 recognized Ser-Gly-CS-stub epitope on the
high molecular weight cartilage CSPG,26 an epitope that
is common in high molecular weight CSPGs.3 Previous
biochemical studies indicated the presence of at least
four CSPG species in HT168 cells having approximate
molecular weights of 1000, 600, 500, and 400 kd based
on the Kav values on Sephadex CL 4B.28 However, only
the 1 000-kd species was characterized by hialuronic
acid (HA) binding capacity.28 HA-binding characterizes
several CSPGs including aggrecan, versican, PG-M,
aortic high molecular weight CSPG2,3, as well as
meICSPG.1718 Furthermore, there are immunologic sim-
ilarities between the high molecular weight CSPGs.3 In-
terestingly, melanoma CSPG antigen was detected not
only in human melanomas but in other tumor cell types as
well as in some normal cells including chondrocytes.29
Decreased expression of a common CSPG motif, Ser-
Gly-CS-stub, in the highly metastatic melanoma cells,
HT168-Mi, may affect the CS-biosynthesis as well. On
the other hand, there was no difference between the lines
in the expression of melanoma specific CSPG antigen,
which supports those previous observations that the ex-
pression of this antigen is not linked to the progression.18
The fact that in highly metastatic melanoma cells the high
molecular weight CSPG disappeared28 when no alter-
ation was found in meICSPG epitope expression sug-
gests that the high molecular weight HA-binding CSPG in
HT168 cells is most probably not the meICSPG. Further
studies have been undertaken to solve this question.
More characteristic differences were found in base-
ment membrane-type and surface-type HSPG expres-
sion in our human melanoma cells. There was an in-
creased surface HSPG epitope expression in the HT1 68-
Ml highly metastatic line; however, the majority of those
surface HSPG antigens was masked by trypsin-sensitive
domains. Interestingly, there was no difference in the in-
tracellular expression of HSPG antigens between the two
melanoma lines. Morphologic study showed that in the
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Figure 6. Incorporation of 3H-glcN into sGAGs of melanoma cells. Data are expressed in cpm x 1C3/105 cells. Bars represent means of3
samples ± SD.
highly metastatic cells, the surface-type HSPG-antigens
recognized by the PAb FW1 6, was localized not only on
the apical plasma membrane but at the substrate at-
tached membrane areas, suggesting that, at least this
HSPG, may play a role in attachment. The meICSPG an-
tigen was not present at those areas in the HT1 68/HT168-
Ml model, on the contrary to previous reports in another
melanoma line.30 The A2058 human melanoma cell line,
the parent line of the HT1 68 tumor xenograft, contains at
least two different HSPG species,3132 a hydrophobic
transmembrane molecule with high affinity to thrombo-
spondin and a basement membrane-type HSPG with
high affinity to fibronectin.31 In fact, in HT1 68/HT1 68-Mi
cells we have shown the presence of two HSPG species
characterized by -200 and -400 kd32 and in harmony
with this, in the present work, we found binding of an
anti-basement membrane (PAb BN42) and anti-plasma
membrane (PAb FW16) HSPG antibody to HT168/
HT168-M1 cells. The lower level of expression of surface
HSPG antigens in low metastatic HT1 68 cells is due to an
intracellular accumulation or retention of these molecules
as it was proven by biochemical measurements.32
The function(s) of PG molecules in human melanoma
cells is still unknown. They might play an important role in
matrix adhesion1' 34 but according to recent observations
they might be involved in the autocrine regulation of the
cell proliferation as well.6 Functions of HSPGs and
CSPGs are frequently opposite in adhesion and cell pro-
liferation.1'3,4, Our present and previous results21 sug-
gest that absolute or relative dominance of HSPGs over
CSPGs at the surface of human melanoma cells could be
considered as a marker of a more metastatic phenotype.
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